As of 2:30 PM on the 18th, Medytox is trading at 194,500 KRW, down 4.66% from the previous day. The trading volume is 478,791 shares, which is about 31.8% of the previous day's volume. Medytox is known as a manufacturer and seller of pharmaceuticals and cosmetic pharmaceuticals.


On December 18, Minjung Seon, a researcher at Hana Financial Investment, stated, "Victory in the ITC final ruling. With this ITC final ruling, Medytox has legally confirmed that its strains and manufacturing processes were misappropriated, firmly securing its justification. The important point is not the 21-month and 10-year import ban periods, but the judgment that misappropriation occurred. The uncertainty related to Medytox's strain controversy can be considered resolved. Now is the time to focus on Medytox's fundamentals. Pay attention to the performance improvement of Medytox, which has secured clear justification." She set Medytox's target price at 400,000 KRW.


Over the past five days, individual investors have net purchased 39,853 shares of Medytox, while foreigners and institutions have net sold 35,724 shares and 7,613 shares, respectively.



※ Source: AI Investment Assistant AI Rassiro


※ This article was generated in real-time by an automated article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing